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The increase in allergic diseases in Westernized Countries is an established phenomenon, 
which has been extensively documented by several large epidemiologic studies (Sicherer 
and Leung, 2010). Allergies affect nowadays a proportion of the general population as large 
as one out of five individuals. The most prevalent clinical expression of allergies include 
respiratory allergies, such as allergic rhinitis and asthma (Chu et al., 2010), skin allergies, 
such as atopic dermatitis (Spergel, 2010a), and food allergies (Chafen et al., 2010). The 
pathogenesis of allergic diseases, and the reasons for their increased incidence is partially 
known and include environmental and genetic factors (Kuriakose and Miller, 2010). In all 
cases, the hallmark of all these bone fide allergic diseases is the presence of specific antibodies 
of the immunoglobulin E (IgE) isotype against protein antigens, which are indicated as 
allergens on the basis of their capability to elicit allergic reactions. The presence in the 
biological fluid of IgE to a given allergen is indicated as “sensitization” to that allergen. In 
most cases, IgE are measured in serum, where they are more easily detected and also on the 
ground that allergy is a systemic condition, with clinically relevant expression in different 
individuals at different target organs (e.g., lower respiratory tract in the case of allergic 
asthma, nasal mucosa in the case of allergic rhinitis, etc.) (Pucci and Incorvaia, 2008) 
depending on organ-specific characteristics, which have been only partially identified. 
The correct identification of sensitizing allergens is required to put in action the most 
efficient strategies to counteract the clinically relevant effect of allergies as well as their 
remarkable effects on the quality of life (Cummings et al., 2010). Useful measures include 
allergen avoidance, when applicable, proper symptomatic therapy and, most importantly, 
allergen specific immunotherapy, which is the only intervention capable to actually modify 
the pathogenic mechanisms of allergic diseases and their natural history, known as the 
allergy march (Spergel 2010b). 
IgE can be measured in vivo with prick testing and in vitro with immunochemistry testing. 
Notably, as compared to immunochemistry testing of other immunoglobulin classes, 
specific enhanced procedures have to be used for allergen specific IgE determination, due 
their concentrations in biological fluids, which is in the range of ten to hundred thousand 
times lower as compared to the most represented immunoglobulins, e.g., those belonging to 
the IgG isotype. A major issue to be considered in allergen-specific IgE determination is the 
quality of the antigen to be used for testing. Indeed allergens, which are encountered by 
patients in natural context are complex mixtures of relatively heterogeneous proteins. This 
fact poses several problems to Manufacturers of allergen extracts, including the 
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standardisation of procedures used to obtain them from raw allergen sources and the 
possibility that they are not fully representative of the actual contents in terms of allergen 
components, as compared to environmental allergen sources. In the last twenty years the 
advent of molecular allergology has introduced revolutionary changes in the possibility to 
properly diagnose and treat allergic individuals by using single allergen components rather 
than allergen extracts. Molecular allergology has also made it possible to standardize 
allergen extracts themselves, which can now be used with a much higher knowledge about 
their appropriateness as diagnostic or therapeutic tools in patients with sensitization profiles 
defined at the level of single allergen components. 
Allergen products require registration by government institutions (Becker et al., 2006), such 
as the FDA in the United States and the Paul Ehrlich Institute in Germany. Basic researchers, 
physicians, regulatory authorities and manufacturers have long tried to define a common 
methodology to standardize allergen vaccines (Terho and Frew, 1995; van Ree et al., 2008) 
The quality of mite and pollen allergen extracts is better defined today than it was in the 
past, and the quality of food and epithelial allergen extracts has also improved (Fernandez-
Caldas et al., 2006; Ferrer et al., 2005). However, further improvement is needed, particularly 
for food allergen extracts, since preliminary studies have shown efficacy also in this hi-
impact clinical application, using sublingual food allergen extracts (Enrique et al., 2005). 
Thus, the heterogeneity of allergen extracts used for diagnosis and immunotherapy makes it 
necessary to develop methodologies to assess their potency and ensure their consistency, 
stability and safety. In general terms it is essential to apply standardization in order to 
control all aspects of the production process, including the variability intrinsic to the source 
materials and the consistency and reproducibility which have to be granted for the sake of 
safety and efficacy in the clinical use (diagnosis, immunotherapy, quantification of 
environmental allergens).  
Nowadays, different types of standardizations are still largely used by different laboratories 
and manufacturers, which variably addresses crucial issues underlying these preparations, 
such as the qualifications applied to collectors of raw materials, the establishment of 
manufacturing procedures in compliance with good manufacturing practice (GMP) 
regulations, and the choice of formulations of allergen extracts intended for clinical use 
(Larsen and Dreborg, 2008).  
Although a limited number of major allergens (King et al., 1994) stimulate IgE production in 
a greater part of patients, any antigen in a given source material has the potential to elicit an 
IgE response. Thus, on one side it is essential to ensure that all protein allergens in the 
allergenic source material, to which humans are exposed in real life, are actually contained 
in the raw material used for diagnosis or immunotherapy. On the other side, since the IgE 
binding capacity of an allergen extract is related to the content of one or a few major 
allergens, it is also important that the standardization procedure ensures consistency, not 
only in the overall IgE binding potency, but also in the relative and absolute content of 
single major allergens. Due to this complexity in the composition of allergen extracts, the 
use of standards is a key element in standardization (Lowenstein, 1987). In Europe, each 
laboratory and manufacturer establishes In-House Reference (IHR) preparations for each 
source material. The IHR must be thoroughly characterized by in vitro methods as a basis for 
equilibration of subsequent batches. These methods have traditionally been based on whole 
extracts, whereas only in the last decade reference to single allergen components has been 
progressively introduced. Although it is still widely supported the notion that the biological 
activity of allergen extracts (also known as “allergenicity” or “reactogenicity”) has to be 
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determined in humans by in vivo methods, i.e. prick testing, it is time for all stake-holders to 
be put in the position to compare each new batch by using in vitro methods exclusively. In 
order for this advancement to be achieved, international standard (IS) preparations should 
be made available and in vitro methods should be validated by international health 
authorities for each allergen source. All laboratories in the world should be put in the 
condition to compare the allergen contents of extracts, which are used in everyday clinical 
practice to diagnose and treat such a large proportion of the population. This chapter 
describes the principles and problems related to standardization of allergen extracts for 
research and clinical use. 
2. Mechanisms of allergy 
The immune system of allergic individuals is erroneously reacting against innocuous 
molecular markers of environmental elements, as if they were markers of invaders, i.e., 
virus, bacteria or parasites, which could potentially impair the integrity of vital functions. 
Allergen specific IgE are the immunological heralds of such a reactivity, which was 
evolutionarily developed in mammals to react against parasites (Chinen and Shearer, 2007). 
Circulating basophils (and tissue resident mast cells) are the short-term reacting effector 
cells, which are activated when allergen-specific IgE, bound to their membranes via Fc 
epsilon receptor type I (indicated as “cytophilic IgE”), are triggered by allergen binding to 
release inflammatory mediators stored within secretory granules (Abramson and Pecht, 
2007; Holowka et al., 2007; Macglashan, 2005). Remarkably, the action of these mediators 
takes place within a few minutes since allergen recognition, and includes as dramatic 
changes of the local tissue as increased permeability of the microvasculature, egress of 
several types of inflammatory cells, mainly lymphocytes and eosinophils, secretion of large 
amounts of fluid secretion from mucosal glands and contraction of smooth muscle fibres 
(Barrett and Austen, 2009; Hamid and Tulic, 2009; Holgate, 2008). The latter may induce 
bronchial constriction, which is clinically expressed as asthma. Allergy therapies include not 
only symptomatic drugs, which provide release to the short-term effects associated to the 
release of these mediators (Al Suleimani and Walker, 2007; Bush and Saglani; Novak, 2009), 
but also allergen avoidance and specific immunotherapy. Only allergen avoidance and 
specific immunotherapy can radically modify the course of allergic diseases. However, 
avoidance, which per se is always dramatically effective, can in most cases rather help 
patients to live together with allergy than preventing its effects (Dykewicz and Hamilos, 
2010; Hamilton, 2010; Simons, 2010), due to the fact that exposure to most sensitizing 
allergens in the population is virtually unavoidable. In contrast, immunotherapy is a disease 
modifying intervention, which can change the pathogenesis of the underlying allergic 
condition (Akdis and Akdis, 2010). For all allergy therapies the proper identification of the 
sensitizing allergens is a prerequisite for success (Hamilton) and only the careful 
standardization of hundreds of allergens identified until now allows put in action accurate 
and effective therapeutic interventions (Mothes et al., 2006; Pittner et al., 2004; Valenta et al., 
2007). In particular, in the case of immunotherapy, the performance of the diagnostic 
procedures is mostly crucial, since it influences the appropriateness of years-long 
procedures patients have to undertake (Hankin and Lockey, 2010) in order for their immune 
system to modify reactivity to armless antigens (Abramson et al.; Calamita et al., 2006; 
Radulovic et al.,  2010). In front of this widely accepted circumstances, the determination of 
allergen specific IgE is still performed with criteria which do not allow to distinguish rather 
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common occurrences which make it difficult or impossible to properly define the sensitization 
profile of allergic patients. Indeed, approximately 75% of allergic individuals are poly-
sensitized, i.e. they produce IgE reacting with multiple allergen sources (Scala et al., 2010). 
This polyreactivity can in some cases be attributed to IgE reacting to major allergen 
components in different allergen sources, i.e., it is associated with bona fide multiple allergies 
in clinical terms. However, in as much as one third of cases IgE react to multiple allergen 
components to the presence of IgE to evolutionarily conserved, structurally homologous 
allergen components, which are collectively indicated as panallergens (Hauser et al., 2010). 
In particular, the most common panallergen, profilin, has been found targeted by IgE is as 
many as 50% of subjects sensitized to grass and birch pollens (Chapman et al., 2007). On a 
clinical stand point, as a food allergen profilin usually elicits mild reactions, such as oral 
allergy syndrome, is not modified by processing and is especially important in allergy to 
some fruits, such as melon, watermelon, banana, tomato, citrus fruit and persimmon (Santos 
and Van Ree, 2010). In front of this well-defined scenario, diagnosis with allergen extracts 
cannot distinguish subjects sensitized to major allergens of those extracts from subjects 
sensitized to one profilin cross-reacting in one extract with profilin of one or more extracts 
tested in parallel. There are several negative outcomes stemming from this situation, among 
them the most disturbing are the following: patients do not receive suitable information to 
evaluate their allergic disturbances and are not prescribed proper immunotherapy. In fact, 
although allergen specific immunotherapy with single allergen components is not yet 
commercially available, yet the limits of extract-based diagnosis are certainly capable to 
negatively affect the management of extract-based immunotherapy. Most allergists do not 
prescribe immunotherapy to patients with a polysensitization pattern, without investigating 
whether this pattern is ascribed to a real multiple allergies rather that to cross-reactivity via 
panallergens, despite the fact that clinical benefits have been reported in immunotherapy-
treated polysensitized subjects (Ciprandi et al., 2010a; Ciprandi et al., 2010b). Thus, the present 
knowledge of the pathogenesis of allergic diseases has dramatically improved on the ground 
of increased cloning of allergen components but it is still waiting a thorough change in the 
clinical management of patients, due to the poor application of molecular allergology to the 
principles of allergen standardization. Along this line, the natural history itself of allergic 
diseases may be more efficaciously dissected by using allergen components than extract. For 
instance, a functionally relevant T-cell response to conserved regions of panallergens was 
demonstrated to underlie the possibility in single patients allergic to one given allergen to 
react against another allergen source expressing a homologous, conserved component, such 
as a profilin. These results suggested that a reciprocal modulation of the response to one 
sensitizing allergen can occur following natural exposure to or immunotherapy with 
another allergen and may certainly have relevance in the management of patients with 
multiple allergies (Burastero et al., 2004). Thus, extract-based diagnosis and immunotherapy 
need to be standardized also on the ground of the possibility to properly monitor the 
evolution of allergic disturbances. In the next future all stake holders, patients first, will 
have to fully exploit the remarkable advancements that molecular allergology allowed to 
achieve over in-house reference extracts based allergology of the previous century.  
3. Standardisation of allergens for allergy diagnosis 
The diagnosis of allergic disease requires, besides a detailed history and physical 
examination, the determination of allergen-specific IgE (Hamilton, 2010). In order for this 
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diagnosis to be properly performed, preparations containing allergens have to be utilized, 
both for in vivo and for in vitro testing. In vivo the presence of IgE can be detected with a low-
cost procedure, which provides results in a matter of minutes, known as prick testing. Prick 
testing is performed by creating a 1-mm deep wound with a skin pricker, which put in 
contact single solutions containing each allergen to be tested with skin mast cells. These 
mast cells mediators include histamine and leukotrienes, which promptly increase the 
permeability of local vessels and generate erythema and oedema, a local effect read locally 
as “wheal and flare reaction”. By measuring the size of the wheal, the extent of the 
degranulation is semi-quantitatively assessed, and can be used as an approximate measure 
of IgE levels. A part from the efficacy of the allergen extract used for prick testing, several 
other individual factors affect the results of this procedure, such as individual reactivity to 
histamine, age and sex of the pricked person, the site of reaction, the presence of non specific 
irritants, such as environmental pollutants, the season of the year, etc. (Bordignon and 
Burastero, 2006). This biological background has long represented a major limit in the 
possibility to accurately assess the allergen content of preparations containing allergens for 
diagnostic purposes. 
In fact, allergen extracts are complex mixtures of protein materials obtained by 
Manufacturers from relevant allergen sources and the possibility to easily assess skin 
reactivity by sensitized subjects has long represented the criterion for assessing the 
appropriateness of each preparation (Fernández-Caldas et al., 2009). Indeed, this biological 
approach has obvious advantages over more complex analytical approaches, since it 
warrants to any Manufacturer the possibility to validate the allergen extracts they 
commercialize. However, this method also brings about a peculiar and an extremely 
complex set of standardisation problems, which –incidentally- are not shared by the 
remaining pharmaceutical industry. Firstly, in the absence of any obvious general criterion 
to assess the allergen content with a simple analytical approach, as the one that could be 
applied to measure the active substance in any drug preparation, each Manufacturer is 
encouraged by trivial commercial reasons to maintain strictly confidential all the relevant 
details of preparation procedures. This confidentiality is often used to claim that one given 
specific preparation is better performing as compared to that of competitors on several 
grounds. The latter include the efficiency of allergen recognition by patients IgE, the 
representativeness of the allergen source found in the environment in real life by patients, 
the capability to trigger clinically relevant symptoms and, last but not least, batch-to-batch 
consistence. As a matter of fact, all these criteria are rather difficult to verify on a scientific 
ground, not only because they are related to totally or partially unveiled industrial 
procedures but also because they are applied to complex protein mixtures.  
Indeed, several studies have reported differences among commercially available diagnostic 
products for skin prick testing, see for instance Pagani et al. (Pagani et al., 2009). Another 
study quantified and compared the allergen content of different grass pollen preparations 
for skin prick testing (SPT) used in Europe (Sander et al., 2009). Strikingly, protein 
concentrations ranged from 15 to 427 µg/ml, and the concentration of Phl p 5, a major grass 
allergen, ranged from 0.15 to 18.3 µg/ml (Sander et al., 2009). Major allergens are allergen 
components within a given allergen source, which are recognized by the majority of patients 
sensitized to that allergen source, as established by gold standard criteria (Grier et al., 2002). 
Gold standard criteria include the appearance of clinical symptoms upon environmental 
allergen exposure and thus represent the most incontrovertible parameter of efficacy. Yet, 
extracts are still preferred to allergen components on the ground that conformational 
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epitopes may not be properly expressed in single E. coli cloned and expressed protein 
allergens (Pomes, 2009), that glycosilation, which contribute to allergenicity (Shakib et al., 
2008), is not maintained in recombinant allergens, and that a panel of several, yet to be 
completely defined, allergen components has to used to replace the comprehensive 
repertoire of protein allergens within an extract. Along this line, the quantification of single 
allergen components is considered an unsatisfactory criterion to define the characteristics of 
allergen extracts. Extracts in the United States are more homogenous with respect to total 
allergenic potency than the extracts produced in Europe, mainly because the FDA provides 
the same standardized reagent for internal use by all manufacturing companies (Slater, 
2004). However, great differences have also been shown among non-standardized mold 
allergen extracts in the USA (Esch, 2004). 
4. Standardisation of allergens for immunotherapy of allergic diseases  
Specific immunotherapy is the practice of administering gradually increasing doses of 
allergen vaccines to reduce allergic symptoms and the need for medications. Thus, 
immunotherapy is the only curative intervention in the treatment of allergies, since it can 
modify allergen-driven immunological responses and restoring, to a certain degree, the 
Th1/Th2 balance (Akdis and Blaser, 2001). B and T lymphocytes, blocking antibodies, IL-10 
and other cytokines play an important role in the response to specific immunotherapy 
(Chinen and Shearer, 2004). Effective allergen immunotherapy depends on the accuracy of 
the diagnosis and on the usage of well-characterized allergen extracts. The latter should 
ideally be prepared according to a patient-tailored approach, whereby only allergen 
components one given patient is sensitized to are administered (Vrtala, 2008). Although 
available allergen preparations do not allow this approach, yet numerous double-blind 
placebo-controlled studies using unmodified aqueous allergens (Gurka and Rocklin, 1988) 
and allergoids (Ferreira et al., 2006) (modified allergens) have demonstrated efficacy. 
Sublingual immunotherapy, using drops of aqueous allergen extracts under the tongue and 
then swallowed (Radulovic et al., 2010), or tablets (Bufe et al., 2009; Dahl et al., 2008) with 
similar type of extracts, also appear to be clinically beneficial, particularly for grass-induced 
rhinoconjunctivitis. 
The comparison of different products from different companies at national and international 
levels is complicated due to the lack of international standards, similarly to the above 
quoted problems related to diagnostic products. Larenas-Linnemann and Cox (Larenas-
Linnemann and Cox, 2008) reviewed the information obtained on unit definition and dosage 
of allergens from European manufacturers of allergen extracts used for sublingual 
immunotherapy (SLIT). They concluded that the monthly maintenance dose the 
manufacturers recommended for SLIT was 5-45 times higher than the recommended dose 
for subcutaneous immunotherapy. However, since each manufacturer in Europe uses its 
own in house reference preparations and its own units to express potencies, the comparison 
of different products from different companies at national and international levels is almost 
impossible. The amount of major allergens has started to be used, which represent a major 
improvement at least in principle, to overcome a bona fide anarchism, which is strongly 
supported by Manufacturers, in my opinion, for mere commercial reasons. In fact, in the 
absence of simple international units, such as microgram o micromoles, every manufacturer 
is legitimated to predicate the better performances of each own product, on the basis on not-
verifiable statements and procedures. As a matter of fact, details on the procedures for 
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allergen standardization, which are listed and described in paragraphs below, are never 
made publicly available on the ground of industrial protection issues. Thus, an inviolable 
system tends to self-perpetuate, which is hard to be challenged by the physiological 
dialectic, which should drive scientific issues towards their solution. Along this line, far 
from promoting the usage of homogeneous testing to quantify major allergen contents (e.g., 
same protocols, same monoclonal antibodies for capture and detection in sandwich ELISA, 
etc.) most commentators and opinion leaders support the notion that since the reference 
extracts and antibodies used can influence the outcome of such assays (Larsen and Dreborg, 
2008) basically there is no strong scientific basis to move from good old in-house reference 
units to micrograms of major allergens. This position certainly makes it less embarrassing to 
comment on the fact that the maintenance doses of the commercially available vaccines have 
been found to range from 0.2 to 21.6 µg in terms of Phl p 5 content (Larenas-Linnemann and 
Cox, 2008) which should per se indicate that in house reference should be limited to internal 
quality control procedures. Moreover, doctors and patients should be made really aware of 
what they are actually continuously administering or assuming, respectively, for the 
average two to four years treatment time, rather than counting on the reassuring, only 
partially verifiable statements of Manufactures. 
5. Standardisation of allergens for measuring their environmental amount 
The measurement of allergens in the environment is a well-established approach to assess 
the level of exposure of sensitized individuals in real life settings. This applies mainly to 
dust mite, animal allergens, cockroach, and molds. Epidemiologic studies, population 
surveys, and birth cohort studies have plainly defined levels of allergen exposure in 
Western populations and found strong associations between exposure and the development 
of asthma (Arbes et al., 2003; Heinrich et al., 2006; Illi et al., 2006; Sears et al., 2003; Sporik et 
al., 1999; Woodcock et al., 2004; Zock et al., 2006). Guidelines have been developed to 
indicate exposure levels that are risk factors for sensitization (Platts-Mills et al., 1997). 
Allergen assays are used for testing the efficacy of allergen avoidance procedures and 
devices and for monitoring clinical trials of avoidance and the efficacy of remediation 
(Morgan et al., 2004; Platts-Mills et al., 2000; Woodcock et al., 2004). These assays are used in 
the US indoor air quality industry for evaluation of allergen exposure in homes, the 
workplace, and public buildings. In this context, although allergen measurements have 
become routine, the same issues, which are commented above about the lack of international 
standard apply here. However those tests, which are routinely used to this aim necessarily 
include the usage of allergen components (mainly in recombinant form) in order to run the 
standard curves, since the latter are the core element of the assay itself, rather than prick 
testing. Thus, the quantification of allergen content in the environment, even in the absence 
of international standards, is expressed in conventional amounts of major allergen by all 
available assays (Hamilton, 2005), rather than according to the obscure and bizarre in-house 
reference units which still prevail in the diagnostic and immunotherapy fields. 
6. International efforts to standardized allergens 
The widespread use of allergen measurements in the fields of allergy, indoor air quality, and 
environmental exposure assessment has created an urgent need for internationally 
recognized purified allergen standards and for validated and certified immunoassays. Due 
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to the common generalized mind-set by manufactures, immunotherapy products are still 
licensed based on their total potency as established by in-house, non-comparable reference 
units. Nevertheless, allergists increasingly use specific allergen measurements for dosing of 
immunotherapy. Maintenance doses of 5 to 20 mg of major allergen are associated with 
clinical improvement after immunotherapy, and natural allergenic products are being 
formulated, at least in part, based on specific allergen content (Nelson, 2007; van Ree, 2007). 
Allergen concentrations should be monitored not only to establish dose-response 
relationships between allergens and treatment efficacy but also to compare allergenic 
products from different manufacturers, and to formulate recombinant allergen diagnostics 
and vaccines (Becker et al., 2006; Chapman et al., 2000; Scheiner et al., 1994; van Ree, 2007). 
Although the progressive characterization of major allergen components and the 
development of techniques to quantify them, such as ELISA systems based on monoclonal 
antibodies, have led more manufacturers to provide information on the major allergen 
content of their extracts, identification of major allergen content is not currently mandatory, 
except for a limited number of extracts, such as cat and ragweed. The World Health 
Organization and some other regulatory government institutions now recommend that 
allergen manufacturers state the content of representative major allergens in mass units for 
their allergen products (Nelson, 2000). However, differences in assays and methodologies 
for measuring the major allergens still preclude direct comparisons among products of 
different manufacturers (Alvarez-Cuesta et al., 2006). In fact, although recombinant 
allergens are being used to develop new diagnostics and vaccines, yet the structural and 
immunologic properties of cloned allergen components had not been systematically 
compared with those of their natural counterparts in international collaborative studies. The 
World Health Organization (WHO)/International Union of Immunological Societies 
Allergen Standardization Sub-committee has been influential in coordinating international 
standardization. The committee established WHO-approved international standards for 
dust mite, dog hair, and birch, timothy, and short ragweed pollens and produced the WHO 
position paper that recommended the use of standardized allergen vaccines of defined 
allergen content for dosing in immunotherapy (Bousquet et al., 1998; Platts-Mills and 
Chapman, 1991). This approach was also endorsed by a position statement from the 
American Academy of Allergy, Asthma & Immunology (Cox et al., 2010). In 1999, the 
WHO/International Union of Immunological Societies Allergen Standardization Sub-
committee initiated a specific program aimed to develop highly purified allergens that could 
be used for the standardization of in vitro assays which is the underlying issue in the 
implementation of this approach. This provided the genesis for a European Union–funded 
study entitled ‘‘Development of certified reference materials for allergenic products and 
validation of methods for their quantification’’ (acronym: CREATE) (van Ree et al., 2008).  
The aim of the European Union CREATE project was to produce international standards of 
purified allergens with verifiable allergen content. Such standards would enable allergen 
manufacturers, academic organizations, and government and regulatory agencies to use a 
common international standard for specific allergen measurements. A second aim was to 
compare the specificity, sensitivity, and reproducibility of ELISAs for allergen analysis. 
Allergens were selected for the project based on the following criteria: (1) the allergen was a 
major allergen of well-documented clinical importance; (2) purified natural and 
recombinant forms of the allergen were available in greater than 20-mg amounts from 
academic or commercial laboratories; (3) there was strong evidence that the recombinant 
allergen had equivalent IgE binding to its natural counterpart and there was extensive 
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structural data on the allergen; and (4) ELISA kits to measure the allergen were available 
from 1 or more laboratories.  
To carry forward with this project, eight major allergens originating from four of the most 
important inhalant allergen sources were selected: Bet v 1 from birch pollen, Phl p 1 and Phl 
p 5 from grass pollen, Ole e 1 from olive pollen and Der p 1 and 2 and Der f 1 and Der f 2 
from house dust mites. Three allergens were found to be suitable as biological reference 
materials; the rest, except rPhl p 1a, did indicate potential for optimization, but only if 
specific aspects of their protein expression processes will be modified. As a result of this 
study, recombinant Bet v 1 and Phl p 5 are being produced under Good Manufacturing 
Practice and presently being evaluated by the European Directorate for the Quality of 
Medicines as biologic reference preparations to be included in the European Pharmacopoeia 
as international standards. Consequently, at least for these allergens, standardization will 
become global and will hopefully permit comparisons among different manufacturing 
sources (Himly et al., 2009). 
A detailed account of the aims, scope, and methods used in the CREATE project has been 
published elsewhere (van Ree et al., 2008) 
7. Techniques for the standardization of allergen products 
Allergen products, which are routinely used to diagnose and treat allergic diseases have 
been used for over 100 years. The quality of these allergen products is a key issue for both 
diagnosis, environmental monitoring of allergen levels and specific immunotherapy, and 
the standardization of allergen extracts is of primary importance to improve their quality 
and offer physicians worldwide a reliable method to diagnose and treat such widespread 
diseases as food allergies and allergic respiratory diseases. In particular, effective diagnosis 
and treatment, using skin test reagents and specific immunotherapy requires the optimal 
amount of allergens for testing and the maintenance dose of vaccine for treatment, 
respectively. Although a tremendous amount of information is available to implement this 
objective, internationally accepted rules are still lacking. The unavoidable empirical steps, 
which are preliminary to the production of allergen extracts form natural allergen sources 
are usually considered the only relevant aspect of the whole standardisation process, since 
this position is instrumental to support the concept that quantification of allergen 
component in weight (or molar) units are non-applicable and misleading. Obviously, any 
single step in the preparation of allergen extract has to treasure decades of previous 
consolidated experience in as trans-disciplinary expertises as zoology, palynology and 
biochemistry. Yet, the final products of such processes will have to be validated by 
international standards, in order to make it possible to evaluate their allergenic potency and 
compare the corresponding preparations of different Manufacturers, if quality is something 
different from a jealously kept secret of happy few. 
8. Collection of raw source materials 
Inhalant allergens are present in airborne particles derived from natural allergen sources. 
These particles constitute the material which humans are exposed to. The selection of raw 
material is finalized to provide extracts containing the same active allergens patients will 
encounter in real life in a manageable form. Although in most cases, the optimal source 
material is rather obvious, in some cases the allergen source is still debated (for instance, for 
cat allergy it is not yet established whether the best allergen source is saliva or dander and, 
www.intechopen.com
 
Quality Control of Herbal Medicines and Related Areas 
 
128 
in the case of mouse allergy, urine or dander). In principle, the source materials should be 
specific and include all relevant components in sufficient amounts to be recognized by 
serum IgE from the whole population displaying clinical symptoms when exposed to the 
corresponding allergen in a real life setting (Lowenstein, 1987). Collectors must be qualified 
to verify the identity and quality of the source materials, so that only specifically identified 
allergenic source materials that do not contain avoidable foreign substances should be used 
in the manufacture of allergenic extracts and methods should be applied to trace the 
materials from their origin. This includes complete identity labelling and certification from 
competent collectors. Avoiding non-allergenic, contaminant material is particularly crucial 
also on the basis of the fact that same doubts were raised about the possibility that 
immunotherapy extracts could raise sensitization to previously non-sensitizing protein 
components. Along this line, the processing and storage of source materials should be 
performed to ensure that no unintended substances, including microbial organisms, are 
introduced into the materials. Records should describe source materials in as much detail as 
possible, including the particulars of collection, pre-treatment, and storage. 
8.1 Pollens 
The natural sources of inhalant allergens from plants are the pollens. Pollen may be 
obtained either by collection in nature or from cultivated fields or greenhouses. The 
collection may be performed by several methods, such as vacuuming or drying flower heads 
followed by pulverizing. In brief, anthers, which are long, slender filaments in a flower that 
have two lobes at the top, are best collected from intact, partially opened buds. The pollen 
may be cleaned either by passing through sieves of different mesh sizes or by flotation. 
Finally, pollens are dried under controlled conditions and stored in sealed containers at -
20°C. The maximum level of accepted contamination with pollen from other species is 1% 
by number. Pollen should be devoid of flower and plant fragments, with a limit of 5% by 
weight. Pollens may show large modifications in quantitative composition depending on 
season and location of growth. In order to achieve a relatively constant composition, 
harvests from different years and sites of collection should be pooled for the production of 
allergen extracts, after thorough in vitro characterization. 
8.2 House dust mites 
House dust mites are grown in cultures and the source materials for mite allergen extracts 
can be represented by either pure bodies or whole mite cultures. Extracts based on whole 
mite cultures include eggs, larvae, and faecal particles as well as mite decomposition 
material and contain all the material to which mite-sensitized individuals are exposed under 
natural conditions. The culture medium should ideally be antigen free or, alternatively, 
contaminants from the culture medium should be shown not to be allergenic. The pure mite 
body extracts avoid extensive contamination with debris from the culture medium. In one 
clinical study, vaccines based on whole mite cultures and pure mite body extracts have 
shown similar clinical efficacy (Wahn et al., 1988). 
8.3 Mammals 
Allergens of mammalian origin may be present in various sources (typically, dander, serum, 
saliva, or urine). The allergens to which humans are exposed depend on the normal 
behaviour of the animal and the optimal source of allergens from mammals should be 
systematically investigated using a large panel of sera from patients sensitized to each given 
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animal. Notably, no matter if they are derived from dander or deposited from body fluids, 
most mammal allergens are present in the fur. Only healthy animals must be used for 
collecting allergens, and post-mortem collection is allowed only in exceptional cases and if 
stringent precautions to minimize decomposition were taken.  
The optimal source materials are often dander, because hair proteins are insoluble. Use of 
whole pelt would increase the proportion of serum proteins, which are generally of low 
allergenic activity. In the case of the popular dog allergen extracts, remarkable differences 
were reported when deriving the material from different dog breeds (Larsen and Dreborg, 
2008; Lindgren et al., 1988), a mixture of material from different breeds should be selected 
representing a balanced content of the major allergens (Uhlin et al., 1984). 
8.4 Insects 
The most common insect allergen is hymenoptera venom, which is brought in contact with 
the human immune system by sting. In this case, the purified venom itself is the best 
allergen source. In more uncommon cases the route of exposure may be biting or even 
inhalation. In this cases whole insects (including insects debris) and saliva are the proper 
allergen source, respectively.  
8.5 Fungi 
Allergens should be extracted by moulds, provided that they are grown under strictly 
controlled conditions (Larsen and Dreborg, 2008). The harvested raw materials should 
consist of mycelia and spores. In order for fungal cultures to maintain constant composition, 
it is recommended that extracts are derived from several independent cultures of the same 
species obtained from established fungal culture banks, i.e., American Type Culture 
Collection. All batches should be derived from the same strain to secure a stable 
composition, since it is well established that they may vary even under apparently 
analogous growth conditions (Steringer et al., 1987; Wallenbeck et al., 1984). The cultivation 
medium should be devoid of allergenic ingredients (i.e., serum proteins) and any safety 
measures should be taken to avoid contamination by any microorganisms, including other 
fungi 
8.6 Foods 
The supply of standardized material for the preparation of food allergen extract is limited, 
due to the complexity of this area. In fact, foods are often derived from various subspecies, 
grown under a broad variety of conditions reflecting geographical variation. Moreover, 
foods are often cooked prior to ingestion, and the cooking procedures may differ 
geographically. Consequently, the source of allergen exposure is highly variable both in 
qualitative as well as in quantitative terms (Lemanske and Taylor, 1987). The possibility to 
prepare sets of food allergen extracts reflecting the local species, the habit of cultivation, 
harvesting, storing, and cooking is a conceptual academic attitude which is raising more 
problems than those it can solve. For this reason, unsatisfactory results have been observed 
from commercially available reagents, which have resulted in many clinicians using 
untreated foods from retail trade for diagnosis by the prick–prick method (Dreborg and 
Foucard, 1983). Examples are fresh fruit, cow’s milk, and hen’s egg. Undiluted cow’s milk 
and hen’s egg have the best-documented diagnostic properties (Verstege et al., 2005). In this 
scenario, the usage of purified food allergen components, in either natural of recombinant 
form appears as a by far more suitable approach to circumvent these limitations. Moreover, 
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the characterization of the profile of sensitization to single allergen components allow to add 
up important clinical information, which cannot be extrapolated from diagnosis with whole 
extracts. For instance, the appearance of IgE to defined allergen components was 
documented in cohorts of milk allergic children (Hochwallner et al., 2010; Ott et al., 2008), 
which allows to follow up the clinical evolution of milk allergy. Another added value stems 
from the possibility to distinguish sensitizations associated with different profile risk. For 
instance, individuals with sensitization to nut allergen extract may have IgE to Cor a 1, 
cross-reacting birch allergens of the Bet v 1-like, PR-10 protein family or to Cor a 2, cross-
reacting with profilins from several different allergen sources (fagales, grasses, pellitory, 
etc.). Alternatively, a positive skin prick test, or in vitro specific IgE determination assay, 
may be associated to the presence of IgE to the Lipid Transfer Protein Cor a 8. The former 
situation is associated with limited clinical symptoms (for instance, oral allergic syndrome) 
whereas the latter may be associated with severe systemic reactions. These two strikingly 
divergent scenarios, which can be referred to the acid and heat sensitivity of profilins and 
PR-10, versus the resistance to physical stimuli of lipid transfer proteins cannot be 
distinguished by extract-based diagnosis. 
9. Preparation of allergen extracts 
Allergens to be used for diagnostic purposes have to be as intact as possible in terms of 
molecular structures, which are recognized by allergic patients’ IgE. Thus, any preventative 
measure has to be taken to prevent denaturation in the preparation and storage of allergen 
to be used for diagnosis or immunotherapy. On this basis, organic solvents, elevated 
temperatures, and extreme pH and ionic conditions should be carefully avoid whenever 
possible. The extraction should be performed under conditions resembling the physiological 
conditions (i.e., physiological pH and ionic strength) and suppressing possible proteolytic 
degradation and microbial growth (Lowenstein et al., 1981; Lowenstein and Marsh, 1981, 
1983). As a matter of fact, the optimal extraction time is usually a compromise between yield 
and denaturation of the allergens, and in general, the processing time is minimized and 
extraction performed at low temperatures. Low molecular weight, i.e., below 5000 Dalton, 
non-antigenic material is removed from the extract by conventional biochemical techniques, 
such as dialysis, ultra-filtration, or size exclusion chromatography. However, it should be 
kept in mind that any substance excluded from the final product must be directly shown to 
be non-allergenic, before being systematically discarded. The final extract should be stored 
either lyophilized or at low temperatures (i.e., -20°C to -80°C). Often 50% glycerol and non-
allergenic proteins (e.g., certified human serum albumin) are used as stabilizers. 
9.1 IHR preparations 
In Europe, the in-house reference preparations (IHR) are prepared by individual 
laboratories or Manufacturers, whereas in the United States, the US Food and Drug 
Administration (FDA) authorizes general standards of some common allergens for the 
purpose. IHR are specifically used by Manufacturers/laboratories for equilibration of the 
potency and composition of each batch of manufactured extract. By this procedure the 
batch-to-batch standardization is performed by comparison to the IHR using in vitro 
techniques exclusively.  
Usually, three batches of the extract are produced in order to verify consistency and 
reproducibility of the production processes. The three batches are compared and, if 
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consistency is achieved, one is selected to represent the new IHR, which is subsequently 
dispended into freeze-dried aliquots of suitable size.  
The IHR is defined by the determination of the dry weight, protein content and 
composition, with particular reference to major allergen content and total allergenic activity 
by in vivo and in vitro methods. The evaluation of total allergenic activity by skin prick 
testing is usually performed only occasionally, i.e., not for all batches, and has been shown 
to correlate with major allergen content (Dreborg and Einarsson, 1992). In general, the use of 
major allergen determination with a validated assay is considered sufficient to validate 
results of IHR units, when combination with a specific IgE potency assay is available. 
However, if in vitro methods alone are used for the establishment of the potency of the IHR, 
comparison is best made with the international standards (IS), which is not available for all 
allergens (see below).  
9.2 International standards 
Besides IHR reparation, allergen extract standardization requires the use of an 
internationally defined standard for each source material, indicated with the acronym IS. IS 
of allergen extracts can be obtained from the National Institute of Biological Science and 
Control, NIBSC, London, United Kingdom (Health Protection Agency, 2010), and are 
produced under the auspices of the WHO according to guidelines established by the 
Allergen Standardization Sub-Committee under the International Union of Immunological 
Societies (IUIS). IS enable comparison of specific activities of products from different 
manufacturers and can be used as calibrators by new producers and laboratories. 
IS are presently available for the following allergen extracts: Ambrosia artemisiifolia (short 
ragweed) (Helm et al., 1984), Phleum pratense (timothy grass) (Gjesing et al., 1985), the house 
dust mite Dermatophagoides pteronyssinus (Ford et al., 1985), Betula verrucosa (birch), and 
Canis familiaris (dog) (Larsen et al., 1988) 
9.3 Units and measure 
The strength or potency of an allergen extract (allergenicity or reactogenicity) corresponds 
the extent of the response it will elicit in human allergic subjects, to be considered as a 
representative population of all individual with clinically relevant symptoms when exposed 
to that given allergen. Allergic patients react to allergen extracts with different strength 
because they are differently sensitized, i.e., they have different IgE levels to different allergen 
components within the extract. Thus, the degree of sensitivity differs from patient to patient 
as well as for each allergen in the extract. Since extracts from different producers differ in 
composition there is no straightforward relationship between potency and response when 
comparing products from different Manufacturers and their potency cannot be compared in 
a satisfactory manner. Prick skin testing of human allergic subjects is the prevalent in vivo 
method for the assessment of allergen extract potency (Platts-Mills and Chapman, 1991) and 
also constitutes the standard underlying the determination of biological units of allergen 
extract potency. In this context, criteria of patient selection are obviously crucial, since potency 
measures will be dependent on pattern of sensitization in the panel of selected patients, 
Moreover, besides the characteristics of the sensitization to single allergen components, 
several other in vivo factors have been reported to variably influence prick test readings, 
such as age, sex, site of pricking, environmental pollution, season of the year (Bordignon 
and Burastero, 2006). According to the Nordic Council on Medicines HEP were adopted as 
the Nordic Biological Unit for allergens, which imply to determine the concentration of 
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allergen inducing a weal of the same size as that of histamine dihydrochloride, 10 mg/mL, 
as evaluated by a skin test run in parallel, in a panel of at least 20 patients attending an 
allergist who poses a diagnosis of allergy to the allergen of interest. The median concentration 
corresponds to 10,000 biological units (BU) (Dreborg et al., 1987). With proper patient 
selection this Unit has been shown to be relatively reproducible between different regions of 
Europe (Dreborg et al., 1987). European manufacturers use their own company-specific 
units, most of which are based on the same method. In the United States, the FDA uses a 
unit based on intra-dermal testing with the allergen extract and subsequent measurement of 
the flare rather than the weal size. This intradermal end point is expressed as the number of 
threefold dilution producing a summed erythema diameter of 50 mm. The mean value of 15 
individuals defines the potency of the allergen extract, which is expressed in Allergy Units 
(AU). Later on, the Center for Biologics Evaluation and Research (CBER) in the United States 
proposed the Bioequivalent Allergy Unit (BAU). The method for assigning BAU is named 
ID50EAL. According to ID50EAL the intradermal dilution for 50 mm sum of erythema 
diameters determines the allergy unit (Turkeltaub, 1987). 
In this context, labelling of the potency of allergen extracts based on the microgram amount 
of single allergen components, as progressively characterized by molecular cloning, to begin 
with the most representative major allergens, represented a revolutionary change in the 
field. Indeed, the major allergen content was found to correlate with the biological activity 
(Dreborg and Einarsson, 1992). If the same antibodies and methodology are used in the 
immunochemical determination of major allergen content determination of major allergen 
content can replace other methods for potency declaration.  
Until a few years ago, each manufacturer used to express the allergenicity of each 
preparation using exclusively In-House Reference Units, without any reference to major 
allergen content. In my opinion, this scientifically unacceptable situation was strongly 
supported on a commercial ground, likely because allowed each manufacturer to prevent 
direct comparison between corresponding preparations of competitors. For more than a 
couple of decades this circumstance prevented allergists to know how far a given 
preparation was performing as compared to the corresponding preparations of the same 
allergen source from other manufacturers. Several surrogate markers were introduced, to 
compensate for this indefensible deficiency, including the bizarre ratio between the amounts 
of allergen used by each manufacturer in sublingual versus subcutaneous immunotherapy 
(Burastero, 2005; Gidaro et al., 2005). Even now that information of major allergen contents 
has become a unavoidable requisite on a cultural ground, although not yet a regulatory 
requirement (Moingeon, 2006), a sort of intellectually ambiguous position is maintained, by 
publicly supporting the notion, in congresses and meetings, that since different 
immunochemical methods are used to quantify such parameters, than it is still legitimate for 
each manufacturer to claim best performance of its own preparation regardless the amount 
of major allergens. As a matter of fact, extract potency can only be compared if at least 
uniform test methods and reference extracts are used (Larenas-Linnemann and Cox, 2008), 
which is by far a more acceptable, although in-development situation, than any alternative 
anarchism. Thus, even if in most cases the composition of test materials and the specificity 
of anti-allergen antibodies vary between laboratories, the content of a single major allergen 
does allow comparison of overall potency between marketed allergen extracts by far 
superior to any previously available methods.  
Rather than persisting in old methods on the ground that the new ones has limits, new 
techniques will have to be developed and extensively applied in the next future to answer to 
www.intechopen.com
 
Allergen Extract Analysis and Quality Control   
 
133 
the following questions: a) How far is one given extract qualitatively representative of the 
repertoire of allergen components which are actually encountered in real life by sensitized 
patients in different areas of the world? b) How much is each allergen component 
quantitatively represented?  
10. Stability testing 
Criteria, methods, and limits for stability are established in a not satisfactory fashion. In 
Europe, a total allergenic activity in the interval between 30 and 300% of the arbitrarily 
defined in house reference titre is accepted. In contrast, US authorities limit the variability to 
50–200% of the labelled activity. The underlying problems in this context are obviously 
related to the lack of precision in methods used of allergenicity measurement. For stability 
assessment the extract should be stored at several different temperatures to assure safe 
storage at room temperature, in a refrigerator, and at 20°C. Accelerated degradation studies 
designed to measure the kinetics of breakdown of the allergen extract can be performed by 
incubation at multiple high temperatures. 
The reference for stability testing is usually the In-House Reference Units itself, a strategic 
choice, which allows each Manufacturer to safely claim superior stability of its own product 
without the risk that controversy can be raised. The application of assays providing results 
in milligram or molar amounts of major allergens are highly needed also for the proper 
evaluation of stability of allergen extracts from different Manufacturers.  
11. Batch-to-batch control 
Having established an In-House Reference Preparation, batch-to-batch standardization is 
still performed by calibrating new freeze-dried batches in bulk with the IHR before 
dispensing into vials for distribution. Batch-to-batch standardization usullay include the 
steps indicated in Table 1 
Although these sophisticated immunochemistry assays are helpful, they do not allow a 
straightforward comparison between different extracts, which could be performed with 
standardized assays based on the weight or molar amounts of major allergens. 
12. Other techniques used for standardization 
Beyond the use of monoclonal antibodies, other physico-chemical approaches have been 
explored for allergen standardization and offer new possibilities. Evaluation of mass 
spectrometry (MS) has been performed to determine its capacity to characterize the 
composition of allergen extracts (Heick et al., 2010; Houston et al., 2010). One advantage 
offered by the use of MS includes the measurement of several different allergenic components 
(allergens and isoforms) simultaneously rather than measuring individual allergens. This is 
advantageous while working with allergen preparations that contain a wide group of IgE 
binding proteins, such as mite extracts. Additionally, MS-based methods are available to 
discriminate between allergen isoforms, which is difficult to accomplish using immunologic 
based methods. This method could also be useful for the standardization of allergoids, since 
measuring major allergens is not possible in these preparations due to their chemical 
modification with aldehyde. The issues with MS-based protocols are that they are not 
quantitative and are not addressed in regulatory policies. Similarly, proteomic approaches 
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are extremely informative about the composition in major and minor allergens within 
complex extracts, although they do not allow provide quantitative results (Corti et al., 2005).  
 
Scope Full description Acronym Ref. 
Determination of dry weight    
Assessment of allergenic 
composition to ensure the presence 
in the final product of all allergens 


















 Isoelectric focusing 
IEF (Brighton, 
1975) 









ELISA (Engvall and 
Perlmann, 
1972) 
Quantification of the total allergenic 
activity 
Radioallergosorbent test 
RAST (Ceska et al., 
1972) 
 RAST-inhibition   
 
Table 1. Steps in batch-to-batch control of allergen extracts 
13. Recombinant allergens and allergen components 
Allergen extracts are complex mixtures of substances, including mainly antigenic 
glycoproteins and variable amounts of non-antigenic, non-protein material, which may have 
some relevance in the trigger and in the establishment of the allergic reaction (Gutermuth et 
al., 2007; Traidl-Hoffmann et al., 2005). Since the beginning of the Nineties, allergen 
components has started to be characterized by molecular biology tools, namely by allergen 
cloning (Valenta et al., 1991), and the complex scenario of the composition of the clinically 
most important allergen sources has been gradually unveiled (Heiss et al., 1999; Kazemi-
Shirazi et al., 2002; Valenta et al., 1999). For instance, presently as many as 50 allergen 
components from the Phleum pratense grass species have been identified 
(http://www.allergome.org/). Phleum pratense is a representative species in the group of 
grasses, which are known to trigger allergic symptoms. It has been extensively 
demonstrated that the homology among corresponding allergen components from different 
grasses is so high that, in the immune system perspective, the derived cross-reactivity of 
grass specific IgE make it possible to simplify grass allergy diagnosis to the point that one 
single species can be used as representative of the whole grass family (van Ree et al., 1998). 
A similar consideration has been extrapolated for Fagales (Van Ree et al., 1999). Thus, on one 
side it is acceptable to narrow down the number of species of a given family of allergenic 
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plants to one representative species, on the other within each given species the complexity 
of the allergen components which are composing the extract has to be considered as 
comprehensively as possible. In fact, it is well established that individuals sensitized to one 
given allergen source are variably reacting with the different antigenic components of the 
raw allergen extract. For instance, grass allergic subjects mainly react against Phl p 1 and Phl 
p 5 allergen components, yet complex patterns of reactivity can be observed in single 
individuals (Rossi et al., 2001; Rossi et al., 2000). Remarkable advantages derived from the 
application of molecular allergology to the overall comprehension of allergic diseases 
pathogenesis, including the understanding the molecular characteristics of allergens, the 
study of allergen structures, the characterization of the humoral (or B-cell-mediated, or 
antibody-dependent) and cellular (or T cell- mediated) immune responses (Burastero et al., 
2004). Moreover, sequence similarity searches have identified the biological functions of 
many allergens and allowed to characterize mechanisms involved in typical allergic 
phenomena such as airway hyper-responsiveness and airway inflammation correlated to 
allergen exposure. For instance, Der p 1 is a glycoprotein with sequence homology and thiol 
protease function similar to the enzymes papain, actinidin bromelain and cathepsins B and 
H (Chua et al., 1988). Only a limited number of clinical trials have been performed until now 
to compare the efficacy of recombinant allergens as compared to raw allergen extracts, 
although clinical benefit when using the former either in native (Jutel et al., 2005; Pauli et al., 
2008) or modified forms (Niederberger et al., 2007; Purohit et al., 2008) have been reported. 
Recombinant allergens will overcome some of the pitfalls of using natural allergen products 
for immunotherapy by enabling physicians to administer only the clinically relevant 
allergens, thus avoiding exposure to unnecessary antigens. In this context, although the 
recombinant allergen era has not started yet for immunotherapy, yet quality control criteria 
must include the quantification of major allergen content in allergen extracts, as an 
invaluable tool to compare extracts from different manufacturers used for diagnosis or 
immunotherapy (Larsen and Dreborg, 2008).  
14. Conclusion 
Methods to achieve the standardisation of allergens used for diagnostic or therapeutic 
purposes should be homogeneous throughout the world. The present situation, whereby 
different Manufacturers use different units generate confusion and unreliable information, 
which may imply either underestimation or overestimation of the potency of allergen 
extracts. These differences may depend on the variability of the raw material used, the 
production methods and the lack of batch-to-batch consistence of the preparation procedure. 
The determination of the content in major allergen is essential to overcome these difficulties. 
Results of the CREATE project highlight a few limitations of recombinant allergen-based 
methodologies, which could support the implementation of this approach. In principle, as 
different factors as incorrect folding, aggregation, poor solubility and insufficient stability 
may affect the possibility to use a given allergen component as reference standard 
(Chapman et al., 2008). Nevertheless, knowledge generated by molecular allergology cannot 
longer wait to be integrated in the know-how to be developed and applied in this scenario. 
Along this line, the European Medicines Agency (EMEA) recommends proving that each 
allergen extract contains the relevant allergens by antibody-based techniques or mass 
spectrometry. In this context, new promising techniques, such as nuclear magnetic 
resonance and small angle X ray scattering, can also be applied to characterize allergenic 
molecules in the laboratory.  
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Overall, this growing awareness is slowly affecting the methods by which allergen extracts 
are standardized. This is a necessary achievement in modern allergology, not only in the 
perspective of better patient care, but also under the prospect of definitely accompanying 
this discipline to the podium it deserves. Development of standardized methods to measure 
allergen content are also eagerly needed by the imminent improvement of specific 
immunotherapy, which will imply the usage of recombinant (or purified) allergen 
components, instead of allergen extracts. This step will definitely promote the development 
of internationally accepted, standardized methods to measure allergen content, and to 
quantify the homogeneity, folding, aggregation, solubility and stability of recombinant 
products. 
There is no doubt about the fact that allergen standardization is a fast developing field, 
which will soon allow to complete the progress of allergology from the present transition 
status where much is still managed according to traditional approaches based on allergen 
extracts and old cuisine to the full implementation of molecular immunology. The dramatic 
social relevance of allergies will warrant the encouragement of the medical and scientific 
community to this transition. 
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